Literature DB >> 16185599

11th World Conference on Lung Cancer of the International Association for the Study of Lung Cancer (IASLC). Barcelona, Spain July 3-6, 2005.

Rafael Rosell Costa.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16185599     DOI： 10.1007/bf02716546

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  6 in total

1.  Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

Authors:  Miguel Taron; Yukito Ichinose; Rafael Rosell; Tony Mok; Bartomeu Massuti; Lurdes Zamora; Jose Luis Mate; Christian Manegold; Mayumi Ono; Cristina Queralt; Thierry Jahan; Jose Javier Sanchez; Maria Sanchez-Ronco; Victor Hsue; David Jablons; Jose Miguel Sanchez; Teresa Moran
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  Extended abstracts of the 11th World Conference on Lung Cancer, 3-6 July 2005, Barcelona, Spain.

Authors: 
Journal:  Lung Cancer       Date:  2005-07       Impact factor: 5.705

3.  Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.

Authors:  Sae-Won Han; Tae-You Kim; Pil Gyu Hwang; Soohyun Jeong; Jeongmi Kim; In Sil Choi; Do-Youn Oh; Jee Hyun Kim; Dong-Wan Kim; Doo Hyun Chung; Seock-Ah Im; Young Tae Kim; Jong Seok Lee; Dae Seog Heo; Yung-Jue Bang; Noe Kyeong Kim
Journal:  J Clin Oncol       Date:  2005-02-14       Impact factor: 44.544

4.  Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

Authors:  Tetsuya Mitsudomi; Takayuki Kosaka; Hideki Endoh; Yoshitsugu Horio; Toyoaki Hida; Shoichi Mori; Shunzo Hatooka; Masayuki Shinoda; Takashi Takahashi; Yasushi Yatabe
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

5.  Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.

Authors:  Teh-Ying Chou; Chao-Hua Chiu; Ling-Hui Li; Chun-Yen Hsiao; Chin-Yuan Tzen; Kuo-Ting Chang; Yuh-Min Chen; Reury-Perng Perng; Shih-Feng Tsai; Chun-Ming Tsai
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

6.  Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

Authors:  H Cortes-Funes; C Gomez; R Rosell; P Valero; C Garcia-Giron; A Velasco; A Izquierdo; P Diz; C Camps; D Castellanos; V Alberola; F Cardenal; J L Gonzalez-Larriba; J M Vieitez; I Maeztu; J J Sanchez; C Queralt; C Mayo; P Mendez; T Moran; M Taron
Journal:  Ann Oncol       Date:  2005-04-25       Impact factor: 32.976
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.